Pharmacokinetic characteristics of fentanyl products
| Bioavailability (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Administration route | Product | Dose tested (μg) | Cmax (μg/l, mean) | Tmax (min, median) | Total | Gastrointestinal | T1/2 (h, terminal elimination) | Reference | |
| Oromucosal | OTFC | Actiq | 800 | 1.0 | 120 | 47 | 25 | 15.3 | Vasisht5 |
| 800 | 1.3 | 91 | 18.3 | Darwish7 | |||||
| Buccal | Breakyl | 800 | 1.3 | 90 | 71 | 20 | 19.0 | Vasisht6 | |
| Buccal | Effentora | 400 | 1.0 | 47 | 65 | 17 | 14.4 | Darwish7 | |
| 800 | 1.7 | 60 | 14.4 | Vasisht5 | |||||
| Sublingual | Abstral | 400 | 0.9 | 57 | NA | NA | 5.4 | Lennernäs9 | |
| 800 | 1.4 | 30 | 10.1 | Lister8 | |||||
| Nasal | With pectin | PecFent | 100 | 0.4 | 20 | NA | NA | 21.9 | Davis3 |
| No pectin | Instanyl | 100 | 1.0 | 11 | >90 | NA | 3.0 | Christrup4 | |
| 0.6 | 12 | Kaasa10 | |||||||
Key results from selected references are presented, and are not intended to provide a comprehensive overview of the data available. Results should be interpreted with care due to interindividual variability and differences between study populations and conditions.
NA, not available, OTFC, oral transmucosal fentanyl citrate.